Skip to main content
. 2014 Feb 28;6:29. doi: 10.1186/1758-5996-6-29

Table 2.

General characteristics in control, diabetic, and diabetic treated with low and high doses of exenatide

  C D DTL DTH
Number
 7
 10
 10
 9
Plasma glucose (mM)
 4.31 ± 0.72
 29.86 ± 1.32*
 29.08 ± 1.20*
 28.66 ± 0.89*
Plasma Insulin (Iu/ml)
 19.36 ± 0.58
 4.91 ± 0.27*
 5.06 ± 0.30*
 5.19 ± 0.31*
Plasma total cholesterol (mM )
 1.46 ± 0.38
 2.79 ± 0.29*
 2.77 ± 0.50*
 2.27 ± 0.72a*,#
Plasma triglycerides (mM )
 0.83 ± 0.13
 1.42 ± 0.20*
 1.29 ± 0.27*
 1.08 ± 0.87#
Plasma free fatty acid (mM )
 1.45 ± 0.20
 2.60 ± 0.41*
 2.26 ± 0.63*
 1.53 ± 0.34#,$
Body weight (g)
 459.57 ± 86.52
 207.70 ± 48.89*
 200.60 ± 74.48*
 211.11 ± 41.20*
Heart weight (g)
 1.30 ± 0.17
 0.93 ± 0.29*
 0.85 ± 0.20*
 0.88 ± 0.23*
Heart/body weight (g/kg) 2.86 ± 0.38 4.50 ± 0.68* 4.42 ± 0.76* 4.42 ± 0.86*

Values were obtained at sacrifice, after administration with or without 8 weeks of exenatide treatment. Control (C), diabetic (D), diabetic treated with low dose (2 μg · kg−1.d−1) of exenatide (DTL), diabetic treated with high dose (10 μg · kg−1.d−1) of exenatide (DTH). All values were expressed as mean ± S.E.M. *P < 0.05 or 0.01 vs. C; #P < 0.05 vs. D; $P < 0.05 vs. DTL.